{"name":"Revolution Medicines, Inc.","slug":"revolution-medicines-inc","ticker":"","exchange":"","domain":"revmed.com","description":"","hq":"Redwood City","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Elironrasib","genericName":"Elironrasib","slug":"elironrasib","indication":"Other","status":"phase_1"},{"name":"Zoldonrasib","genericName":"Zoldonrasib","slug":"zoldonrasib","indication":"Other","status":"phase_1"},{"name":"RMC-9805","genericName":"RMC-9805","slug":"rmc-9805","indication":"Other","status":"phase_1"},{"name":"daraxonrasib","genericName":"daraxonrasib","slug":"daraxonrasib","indication":"Other","status":"phase_3"},{"name":"mFOLFOX6 regimen","genericName":"mFOLFOX6 regimen","slug":"mfolfox6-regimen","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"RMC-6236","genericName":"RMC-6236","slug":"rmc-6236","indication":"Non-small cell lung cancer with KRAS G12C mutation","status":"phase_3"},{"name":"mFOLFIRINOX regimen","genericName":"mFOLFIRINOX regimen","slug":"mfolfirinox-regimen","indication":"Metastatic pancreatic cancer","status":"phase_3"}]}],"pipeline":[{"name":"Elironrasib","genericName":"Elironrasib","slug":"elironrasib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zoldonrasib","genericName":"Zoldonrasib","slug":"zoldonrasib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RMC-6236","genericName":"RMC-6236","slug":"rmc-6236","phase":"phase_3","mechanism":"RMC-6236 is a selective inhibitor of KRAS G12C mutations that blocks oncogenic signaling in cancer cells.","indications":["Non-small cell lung cancer with KRAS G12C mutation","Colorectal cancer with KRAS G12C mutation","Other solid tumors with KRAS G12C mutation"],"catalyst":""},{"name":"RMC-9805","genericName":"RMC-9805","slug":"rmc-9805","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"daraxonrasib","genericName":"daraxonrasib","slug":"daraxonrasib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"mFOLFIRINOX regimen","genericName":"mFOLFIRINOX regimen","slug":"mfolfirinox-regimen","phase":"phase_3","mechanism":"mFOLFIRINOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","indications":["Metastatic pancreatic cancer","Metastatic colorectal cancer","Gastric cancer","Biliary tract cancer"],"catalyst":""},{"name":"mFOLFOX6 regimen","genericName":"mFOLFOX6 regimen","slug":"mfolfox6-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQR3VCRmlZcDVpNTlKWnZZa3JFYWgwTWhrNzBfWDFsTDlVWWx3cmdzWXdUZlNJX09CYmQwcWZWaFkxR0hacVNScjdEdk1uTU5mS1dOQV9aNmVmSktMWXd0Ymo2Y0cyMXpYenZwS1EzRERFNHVuVDNGbWNNTzdpMXYyUkV3c3BKS2piV2JCRkJGblN4WkhVckJ3R3BjQVFpQQ?oc=5","date":"2026-01-26","type":"pipeline","source":"Pharmaceutical Technology","summary":"MSD ends takeover talks with Revolution Medicines - Pharmaceutical Technology","headline":"MSD ends takeover talks with Revolution Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQM3VFN3NSbGI0QXBPOFJtOVlUc0Fndy03NVYwX1pDOUs5ZEc4SEVMX2x4U2FqZHA1dTVsUUZnY0dNRFBlSlU4QzVLaEFNeHFjUXB6NmhHR3pwOUEtZndiOTlJX0hTQmlZQVRKOHFUM3ZCUmpBdG5MeXZ3dGJCVEdwUWV3?oc=5","date":"2026-01-26","type":"deal","source":"pharmaphorum","summary":"MSD said to have pulled back from Revolution Meds deal - pharmaphorum","headline":"MSD said to have pulled back from Revolution Meds deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOSi1COGJjMnJTTjdUelNyczhOcUl0c21PMjhzYnNBaHFiY0RBbTFHVmpFOWdEZjktSVdUTlRPeHRMYlVNcW11YWhZNlVWYS1pcXBYaXlmTGlJcU93eTJ6eExOTHo1NXNKWUpZNk1XbUptdXdfd3dZMlA3c2dSUVpqZXkwNUZUeEN6QTFXR2x2YlRyTDNKdXdoY21qaw?oc=5","date":"2026-01-25","type":"deal","source":"WSJ","summary":"Exclusive | Merck No Longer in Talks to Buy Revolution Medicines - WSJ","headline":"Exclusive | Merck No Longer in Talks to Buy Revolution Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9PQVpHMFI1RGZRaENjQkVTSUVFQ3hpaEZEZGdJc0RlejBRODJiMGJ4LVQ3SWxnYmpvTEdOd1ZsRWFyTHc0dWxpZHY5MWFuUUNSTWJ3?oc=5","date":"2026-01-25","type":"pipeline","source":"FirstWord Pharma","summary":"Merck & Co. backs out of acquisition talks with Revolution Medicines: report - FirstWord Pharma","headline":"Merck & Co. backs out of acquisition talks with Revolution Medicines: report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQbnpWMHN5MGRoMjNsSHlxNHdsRi1RbzA3UnVGeFJSQTlhc0VQbm4wbGh6T1ZkcTZhLWk0X3dzdll4d2Y5RUhVX3I4czdIbE5OcnVRYmdpSHBGSGg1Z0s3Z2swZWNzTmJyUGQ4Q2xiSkE3QzR3ZWlRQ3luaUhMOEdmcTEwOERZWlBhNDBQZkZIM0IwbWZzRU5rRTZDQXNSd2YyMnRhS3lvNzMzWkdqLWtrZ3BsYlUxYUNlUzdmRnZ5cXhCRlhuUk1EMw?oc=5","date":"2026-01-12","type":"deal","source":"Pharmaceutical Technology","summary":"JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree - Pharmaceutical Technology","headline":"JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQOFliVnY4bFFWZG44Y1JIN3c3TTVWYjdDNkZjTC1NbTlCYUNCYVBMWHVTV2dyNVE2bF91Uy1LZW4yVmcwMzM5YW1iOGtseU8xblFwUGFVVEJyc3k1T0R6MDF3azVGbG5rQVNFNEtqZnFVV0VJNjgtRW1NdW1JVlRXckRPQVhMTjFJY0tWaGdaN2laallTZUZzWDJMeTZXM081dG8xX201b0o4NGprZlFBZDNvaHRZeGM?oc=5","date":"2026-01-09","type":"deal","source":"seekingalpha.com","summary":"Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle (RVMD) - seekingalpha.com","headline":"Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle (RVMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPOXhHRHA4OVNBZllGZWVmSWNxX1JmVTNoa3dlRVduVW1LWXUteG11QmdtUHMzVldaeHEtTW5FekUySmtLbnZEYXpwR1BReGpOTEVtVm5oSnFkMzRzVjI4UjJvRFFYOWFHeDJSU3R4MWlldlhqV3d0VFRJQVNKQWd1NlNoRXY5MG42bFpuSkl4ZmZhZjJW?oc=5","date":"2026-01-09","type":"pipeline","source":"Barron's","summary":"Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. - Barron's","headline":"Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQMXlJV3g0RW1XRmQtUUZJa1lQekdQejFCRllPMWFjUUVCODd0MWpUUzlsbUYxV0sxNXF0Z0NtYjdwS280OGJmVzFxdGdfU1BXM25TVHhiWnJncG1tYTlxY3pySmxmdFA0MlF5cVhaRjhsQXotX0FDQ0lFaHFabDBJdFQwSGRHblprd3JQcjJqa0RJYTFoMDIyYVFxd3ZVZng5U0RCbEVuTnVsRGJvVmJoam4xU0YzeS1hUE9VS09BWmNZUnBjMnRJMFEtSWlTcTNPbzBVTGxIZk16Tm9pNXliQkxoUVRubUg3?oc=5","date":"2026-01-09","type":"deal","source":"Benzinga","summary":"Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight - Benzinga","headline":"Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRlUtbTI0R3E5MlFLZ0lJU2ptTURNcmdOdW1faWhBSnZjZ05DM0M4ak1XdTVVUjByQ1hjcGFobmEtVk1hUC16cGo0WTR0cmEzVzFWSkxQTWZJSzhaa1dyR1JDR1pNTnRWTGNsYXhnVHdlbjNXMkUxVmZwU1ZsWjBlM3EtWGlFZGZIc2VXdkdrTFdEOC1iSk40X21DaWxNM09ScmhtZXNCakIzclU?oc=5","date":"2026-01-09","type":"deal","source":"WSJ","summary":"Merck in Talks to Buy Revolution Medicines for Around $30 Billion - WSJ","headline":"Merck in Talks to Buy Revolution Medicines for Around $30 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNSmV4UHdpYnlhaXp6TS1QNTFlUi1UVXdHQXpqX0dWSVBwcmptLXZzQXZFY1M3X2h0SlppeGFLdDVXaEk5RTN1eEIzellBWHJTeDB2cEJMOWV1aWthSnFRR2RxWV9VRTRXY1JKczVfbTNFWGQyeUhnNlBPa0Q3Y0ROODlwT1o?oc=5","date":"2026-01-08","type":"deal","source":"Financial Times","summary":"Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn - Financial Times","headline":"Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQUkVPV3E1eWh0ekxxbENpNEhlMDRPUFBKbnRLMlpaSXNISFpyQzJwMlBkQWRFM0liRGo2QzRMcENGa0RuMmNkSFI5akNTQUQwU3hrSW85RzA0Zm1sRUJFYVVYVHVDOVhUUFQ4a2xTSGRFeFp2a19kdnlLVUZVZExyNVBveXJoVjBUYkg1X0ZmMlRuOHZDanhvUUF4dndxdW9Gbnp6cHBZakpIMnpSWC10WlVsLXc4dEpNcFZsSjRKWGFQOWdnUi14TQ?oc=5","date":"2026-01-07","type":"deal","source":"Reuters","summary":"AbbVie denies media reports of talks to buy Revolution Medicines - Reuters","headline":"AbbVie denies media reports of talks to buy Revolution Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQMF9oamNNajh4Z2hfZTY4a0UxTzhYQjlnM3ZIRWpOQ3o1enBtb3Ricjh0aU9BV3AtRGNVXzE4Z2V6WVZBVWM0X0JRdVlCdHRfUHhMQzJnZ19ubUFWT09wY1pFZ0VaVVRxSHpfMUhteDloeWstM0NuZHlUYUFjVG1Hc1lOX1dzZjJhb1g1bGhrSEpXcnpQVENXMmdBLWo4dEMtXzdXRWN1VmpjRndUa21jUHE0RERsbzI0bS1PaTVDc1dWeW4wQzFVZE9nQzJaSXZuXzdlOHQwTjQ0Yjktbi1iNUhMTUh0UQ?oc=5","date":"2026-01-05","type":"pipeline","source":"GlobeNewswire","summary":"Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire","headline":"Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_1":3,"phase_3":3,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}